Form 4 filings across 7 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: -$37.2M
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 8 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 29 most recent Form 4 transactions.
| $0 |
| $50.8M |
| -$50.8M |
| 5.3M |
| May 6, 2025 |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 86,222 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 965,190 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 102,500 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 2.4M | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 488,891 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 997,299 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV◆ | 9.9M | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | PBUY | 144,443 | $18.00 | $2.6M | +71.2% | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | PBUY | 2.1M | $18.00 | $37.4M | +91.5% | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV | 128,506 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV | 202,862 | — | — | — | Open the original filing on SEC.gov |
| Jan 12 | AKTS | Aktis Oncology, Inc. | CCONV | 2.3M | — | — | — | Open the original filing on SEC.gov |
| Jul 30, 2025 | ADAP | Adaptimmune Therapeutics… | SSELL | 27.4M | $0.1021 | $2.8M | -21.5% | Open the original filing on SEC.gov |
| Jul 29, 2025 | ADAP | Adaptimmune Therapeutics… | SSELL | 2.7M | $0.1012 | $272K | -2.1% | Open the original filing on SEC.gov |
| Jul 28, 2025 | ADAP | Adaptimmune Therapeutics… | SSELL | 33.9M | $0.1125 | $3.8M | -20.6% | Open the original filing on SEC.gov |
| Jun 26, 2025 | ZYME | Zymeworks Inc. | XXITM◆ | 5.1M | — | — | — | Open the original filing on SEC.gov |
| Jun 26, 2025 | ZYME | Zymeworks Inc. | FTAX | 41 | $12.71 | $521 | 0.0% | Open the original filing on SEC.gov |
| Jun 26, 2025 | ZYME | Zymeworks Inc. | XXITM | 5.1M | $0.0001 | $509 | +28.4% | Open the original filing on SEC.gov |
| May 19, 2025 | ZYME | Zymeworks Inc. | PBUY | 5,919 | $11.78 | $69.7K | +<0.1% | Open the original filing on SEC.gov |
| May 15, 2025 | ITOS | iTeos Therapeutics, Inc. | PBUY | 3.3M | $8.00 | $26.4M | +44.7% | Open the original filing on SEC.gov |
| May 15, 2025 | ZYME | Zymeworks Inc. | PBUY | 49,502 | $11.43 | $565.8K | +0.3% | Open the original filing on SEC.gov |
| May 14, 2025 | ITOS | iTeos Therapeutics, Inc. | PBUY | 1.7M | $7.41 | $12.3M | +28.9% | Open the original filing on SEC.gov |
| May 6, 2025 | PRTA | Prothena Corp Public Ltd… | SSELL | 2M | $7.64 | $15.2M | -27.2% | Open the original filing on SEC.gov |
| May 5, 2025 | PRTA | Prothena Corp Public Ltd… | SSELL | 977,693 | $8.11 | $7.9M | -11.8% | Open the original filing on SEC.gov |
| May 2, 2025 | PRTA | Prothena Corp Public Ltd… | SSELL | 3.3M | $8.36 | $27.7M | -28.6% | Open the original filing on SEC.gov |
| Apr 17, 2025 | ZYME | Zymeworks Inc. | PBUY | 54,760 | $11.52 | $630.8K | +0.3% | Open the original filing on SEC.gov |
| Apr 16, 2025 | ZYME | Zymeworks Inc. | PBUY | 73,953 | $11.16 | $825.6K | +0.4% | Open the original filing on SEC.gov |